Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials.
Zoe MoodieStephen R WalshFatima LaherLucas MagangaMichael E HerceSarita NaidooMina C HosseinipourCraig InnesLinda-Gail BekkerNicole A GrunenbergPhilipp MannChenchen YuAllan C deCampMaurine D MinerNicole L YatesJack HeptinstallNonhlanhla N MkhizeOne B DintweNicole FrahmKristen W CohenMary A AllenJulia HutterRalf WagnerGuiseppe PantaleoM Juliana McElrathGeorgia D TomarasLynn MorrisDavid C MontefioriErica Andersen-NissenGlenda Elisabeth GrayPeter B GilbertJames G Kublinnull nullPublished in: PLoS medicine (2020)
In this study, we found that further investigation of DNA/protein regimens is warranted given enhanced immunogenicity to the V1V2 correlates of decreased HIV-1 acquisition risk identified in RV144, the only HIV vaccine trial to date to show any efficacy.
Keyphrases